Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms.

Abstract

OBJECTIVES:

The study is to evaluate biodistribution, dosimetry, safety, and clinical usefulness of F-AlF-NOTA-octreotide (F-OC) PET/CT in combination with F-FDG PET/CT for detection of neuroendocrine neoplasms (NENs).

METHODS:

The biodistribution, dosimetry, and safety of F-OC were evaluated in 3 healthy volunteers. Twenty-two NEN patients underwent PET/CT at 60 minutes after intravenous injection of 3.7 to 4.44 MBq (0.1-0.12 mCi) per kilogram of body weight of F-OC. This was followed by F-FDG PET/CT within a 2-week period.

RESULTS:

F-OC was well tolerated by all healthy volunteers and NEN patients. The calculated effective dose of F-OC was 0.023 ± 0.002 mSv/MBq. In NEN patients, we observed prominent F-OC tumor uptake and high tumor-to-background ratios. Tumor uptake of F-OC was greater than that of F-FDG, and this was particularly evident in G2 NENs (median SUVmax, 45.6 vs 4.3; P < 0.015). Tumor uptake of F-OC or F-FDG was significantly correlated with tumor differentiation (P < 0.05). Dual tracer PET/CT detected more lesions and also yielded information on the biological status of tumors.

CONCLUSIONS:

The tracer F-OC exhibited favorable safety and dosimetry profiles. F-OC provided superior imaging of well-differentiated NENs and significantly higher tumor-to-background ratio compared with F-FDG. Combining F-FDG with F-OC PET/CT has the potential to improve NEN staging and management of patient treatment.

• Authors: Tingting Long, Nengan Yang, Ming Zhou, Dengming Chen, Yulai Li, Jian Li, Yongxiang Tang, Zhaoqian Liu, Zibo Li, Shuo Hu
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 44 Issue 6 Pg. 452-458 (Jun 2019) ISSN: 1536-0229 [Electronic] United States
• PMID: 30985413 (Publication Type: Journal Article)

Chemical References

• Gallium Radioisotopes
• Heterocyclic Compounds, 1-Ring
• Radiopharmaceuticals
• Fluorodeoxyglucose F18
• 1,4,7-triazacyclononane-N,N',N''-triacetic acid
• Octreotide

Topics

• Adult
• Aged
• Female
• Fluorodeoxyglucose F18
• Gallium Radioisotopes (adverse effects)
• Healthy Volunteers
• Heterocyclic Compounds, 1-Ring (adverse effects)
• Humans
• Male
• Middle Aged
• Neuroendocrine Tumors (diagnostic imaging)
• Octreotide (adverse effects)
• Positron Emission Tomography Computed Tomography (methods)
• Positron-Emission Tomography
• Prospective Studies
• Radiometry
• Radiopharmaceuticals (adverse effects)
• Tissue Distribution